February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
6 citations
,
November 2020 in “Clinical Cosmetic and Investigational Dermatology” Both concentrations of triamcinolone acetonide are effective for hair regrowth in patchy alopecia areata, but 5 mg/mL is recommended to reduce side effects.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
1 citations
,
December 2024 in “Dermatology and Therapy” The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
4 citations
,
January 2022 in “Drug design, development and therapy” Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.
11 citations
,
April 2018 in “Epilepsy research” Letrozole reduces seizures but not brain damage in mice.
October 2022 in “Dermatologic Therapy” Both treatments for resistant alopecia areata were equally effective.
A rare skin reaction occurred when a man took paracetamol, causing a new rash in an area already affected by hair loss.
Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.